Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017096100) HETEROCYCLE COMPOUNDS AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096100 International Application No.: PCT/US2016/064507
Publication Date: 08.06.2017 International Filing Date: 02.12.2016
IPC:
C07D 487/04 (2006.01) ,H01L 51/54 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
H ELECTRICITY
01
BASIC ELECTRIC ELEMENTS
L
SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR
51
Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
50
specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
54
Selection of materials
Applicants:
SHANGHAI AEON BIOTECH CO., LTD. [CN/CN]; Room B202-3, Second Floor No. 456 Bibo Road Free Trade Experimental Area Shanghai 201203, CN
Inventors:
ZHAI, Haixiao; US
WU, Fan; US
WU, Zhanggui; US
Agent:
LI, Kening; US
Priority Data:
62/262,39003.12.2015US
Title (EN) HETEROCYCLE COMPOUNDS AND USES THEREOF
(FR) COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
Abstract:
(EN) Compounds having the general formula (I) and pharmaceutical compositions that can be used as Bruton's Tyrosine Kinase (BTK), ITK, JAK3, and selective mutant epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor and their uses in the treatment of related diseases and disorders such as cancer.
(FR) L’invention concerne des composés ayant la formule générale (I) et des compositions pharmaceutiques pouvant être utilisées comme tyrosine kinase de Bruton (BTK), ITK, JAK3, et inhibiteur tyrosine-kinase du récepteur du facteur de croissance épidermique (EGFR-TK) mutant sélectif et leurs utilisations dans le traitement de maladies et troubles associés tels que le cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3007110AU2016362394CN108473496EP3383877US20180346479